ReviewHypertension (Dallas, Tex. : 1979)2021
Heart Failure Primary Prevention: What Does SPRINT Add?: Recent Advances in Hypertension.
Review in Hypertension (Dallas, Tex. : 1979), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Safety and efficacy of angiotensin receptor neprilysin inhibitor in improving cardiac function and blood pressure in dialysis patients.Frontiers in medicine · 2024Pooled it
- Natriuretic peptides and cardiac troponins in hypertension and heart failure: A contemporary review of the evidence.Journal of human hypertension · 2026Review
- Correlation between pharmacologic blood pressure-lowering intensity and improvement in cardiac function in patients with acutely decompensated heart failure.BMC cardiovascular disorders · 2026Article
- 2024 Thai guidelines on the treatment of hypertension.Asian biomedicine : research, reviews and news · 2025Article
- CD36 attenuates pressure overload-induced myocardial insulin resistance via HSF1-dependent HSP90α suppression and competitive disruption of the HSP90α-InsR complex.Journal of translational medicine · 2025Article
- [Cardiorenal syndrome: causes, diagnosis and treatment of congestive nephropathy].Innere Medizin (Heidelberg, Germany) · 2025Review
- Cardiorenal Syndrome in Heart Failure with Preserved Ejection Fraction: Insights into Pathophysiology and Recent Advances.Cardiorenal medicine · 2025Review
- Renal sympathetic denervation improves pressure-natriuresis relationship in cardiorenal syndrome: insight from studies with Ren-2 transgenic hypertensive rats with volume overload induced using aorto-caval fistula.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Effects of sacubitril-valsartan in patients undergoing maintenance dialysis.Renal failure · 2023Article
- SPRINT Revisited: Updated Results and Implications.Hypertension (Dallas, Tex. : 1979) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Hypertension is the most prevalent modifiable factor for the development of heart failure. However, the optimal blood pressure (BP) target for preventing heart failure remains uncertain. The SPRINT (Systolic BP Intervention Trial) was a large, randomized open-label trial (n=9361 participants) that showed the superiority of a systolic BP target of <120 mm Hg compared with <140 mm Hg, with a 36% lower rate of acute decompensated heart failure (ADHF) events. This beneficial effect was consistent across all the key prespecified subgroups, including advanced age, chronic kidney disease, and prior cardiovascular disease. Participants who had an ADHF event had a markedly increased risk of subsequent cardiovascular disease events, including recurrent ADHF. Randomization to the intensive arm did not affect the recurrence of ADHF after the initial ADHF event (hazard ratio, 0.93 [95% CI, 0.50-1.67];
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.